Business
Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting
Updated interim results with an additional ~12 weeks of follow-up since prior update at ASCO-GI in January 2026 and ~25 weeks since ESMO in October 2025Safety update presented on all 64 patients who received at least one treatment and updated efficacy analysis presented on the two patients in Cohort 1 and 23 patients in Cohort 2Objective response in 43% (10 out of 23) of patients in first half of Cohort 2, including an additional new response and confirmation of the initial response reported at
![Perspective Therapeutics Presents Updated Interim Data of [212Pb]VMT-α-NET in Its Ongoing Phase 1/2a Clinical Trial at the 2026 AACR Annual Meeting](https://media.zenfs.com/en/globenewswire.com/a27565ee8edf0640bed1250d2c58f3a9)
About this update from Perspective Therapeutics, Inc.
[{"type":"image","alt":"Perspective Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Perspective Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":63,"url":"https://media.zenfs.com/en/globenewswire.com/a27565ee8edf0640bed1250d2c58f3a9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/uywiRb44xQiC6WhbcBRlmg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg4/https://media.zenfs.com/en/globenewswire.com/a27565ee8edf0640bed1250d2c58f3a9","width":300,"height":63}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Updated interim results with an additional ~12 weeks of follow-up since prior update at ASCO-GI in January 2026 and ~25 weeks since ESMO in October 2025","length":152,"tagName":"p"}]},{"val":[{"type":"text","content":"Safety update presented on all 64 patients who received at least one treatment and updated efficacy analysis presented on the two patients in Cohort 1 and 23 patients in Cohort 2","length":178,"tagName":"p"}]},{"val":[{"type":"text","content":"Objective response in 43% (10 out of 23) of patients in first half of Cohort 2, including an additional new response and confirmation of the initial response reported at ASCO-GI 2026","length":182,"tagName":"p"}]},{"val":[{"type":"text","content":"Nine patients experienced deepening of response since the ESMO presentation ","length":75,"tagName":"p"}]},{"val":[{"type":"text","content":"[212Pb]VMT-α-NET continues to be well-tolerated ","length":47,"tagName":"p"}]},{"val":[{"type":"text","content":"Initial efficacy data from additional 23 patients in Cohort 2 and first eight patients in Cohort 3 expected later this year ","length":123,"tagName":"p"}]},{"val":[{"type":"text","content":"On track to submit a robust clinical evidence package for presentation to more medical conferences and for regulatory engagement in 2026","length":136,"tagName":"p"}]},{"val":[{"type":"text","content":"Additional cohorts and subgroup analysis ongoing to optimize potential registration study design and add optionality ","length":116,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1009,"olType":false},{"type":"text","content":"SEATTLE, April 20, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments ...